Is indinavir crystalluria an indicator for indinavir stone formation?

AIDS

Volumn 15, Issue 8, 2001, Pages 1079-1080

  Salahuddin, Saima ^a   Hsu, Yeffrey S ^a   Buchholz, Niels P ^a   Dieleman, Jeanne P ^a   Gyssens, Inge C ^a   Kok, Dik J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; PROTEINASE INHIBITOR;

ARTICLE; CLINICAL ARTICLE; CRYSTALLURIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; KIDNEY BIOPSY; PRIORITY JOURNAL; STONE FORMATION; URINALYSIS;

CRYSTALLIZATION; HIV PROTEASE INHIBITORS; HUMANS; HYDROGEN-ION CONCENTRATION; INDINAVIR; KIDNEY CALCULI; MALE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; URINALYSIS;

EID: 0035947272     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200105250-00026     Document Type: Article

References (16)

1. 1. Kopp JB, Miller KD, Mican JA, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 1997, 127:119-125.
2. 2. Tashima KT, Horowitz JD, Rosen S. Indinavir nephropathy [Letter]. N Engl J Med 1997, 336:138-140.
3. 3. Trainor I.D, Steinberg JP, Austin GW, Solomon HM. Indinavir crystalluria: identification of patients at increased risk of developing nephrotoxicity. Arch Pathol Lab Med 1998, 122:256-259.
4. 4. Martinez F, Mommeja-Marin H, Estepa-Maurice L, et al. Indinavir crystal deposits associated with tubulointerstitial nephropathy. Nephrol Dial Transplant 1998, 13:750-753.
5. 5. Sarcletti M, Petter A, Zangerle R. Indinavir and interstitial nephritis [Letter]. Ann Intern Med 1998, 128:320.
6. 6. Reiter WJ, Schon-Pernerstorfer H, Dorfinger K, et al. Frequency of urolithiasis in individuals seropositive for human immunodeficiency virus treated with indinavir is higher than previously assumed. J Urol 1999, 161:1082-1084.
7. 7. Anonymus. Crixivan (indinavir sulfate) product monograph. Whithouse Station, NJ, USA: Merck, Sharp and Dohme; 1996.
8. 8. Hermieu J, Prevot M, Ravery V. Urolithiasis and the protease inhibitor indinavir. Eur Urol 1999, 35:239-241.
9. 9. Sutherland SE, Reigle MD, Seftel AD, Resnick MI. Protease inhibitors and urolithiasis. J Urol 1997, 158:31-33.
10. 10. Berns JS, Cohen RM, Silverman M, Tuerner J. Acute renal failure due to indinavir Crystalluria and nephrolithiasis: report of two cases. Am J Kidney Dis 1997, 30:558-560.
11. 11. Dieleman JP, Gyssens IC. van der Ende ME, de Marie S, Burger DM. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS 1999, 13:473-478.
12. 12. Clayman RV. Crystalluria and urinary tract abnormalities associated with indinavir. J Urol 1998, 160:633
13. 13. Kok DJ. Intratubular crystallization events. World J Urol 1997, 15:219-228.
14. 14. Gagnon RF, Tecimer SN, Watters AK, Tsoukas CM. Prospective study of urinalysis abnormalities in HIV-positive individuals treated with indinavir. Am J Kidney Dis 2000, 36:507-515.
15. 15. Kok DJ, Poindexter J, Pak CYC. Calculation of titratable acidity. Kidney Int 1993, 44:120-126.
16. 16. Elliot JS, Sharp RF, Lewis L. Urinary pH. J Urol 1959, 81:339-350.